- Joined
- Mar 28, 2026
- Messages
- 2,843
- Solutions
- 1
- Reputation
- 6,340
==========================================================
WAY-316606 AND sFRP-1 MEGATHREAD
The Complete Evidence-Based Guide
Mechanism | Bone | Hair | Pipeline
==========================================================
Bodine PV et al. (2009). Bone. A small molecule inhibitor of the Wnt antagonist secreted frizzled-related protein-1 stimulates bone formation.
Hawkshaw NJ et al. (2018). PLOS Biology. University of ]
Ma Q et al. (2022). Journal of Bone and Mineral Research. The SFRP1 Inhibitor WAY-316606 Attenuates Osteoclastogenesis Through Dual Modulation of Canonical Wnt Signaling.
==========================================================
TABLE OF CONTENTS
==========================================================
==========================================================
mass tag stolen from @Dragon
==========================================================
WAY-316606 AND sFRP-1 MEGATHREAD
The Complete Evidence-Based Guide
Mechanism | Bone | Hair | Pipeline
==========================================================
Bodine PV et al. (2009). Bone. A small molecule inhibitor of the Wnt antagonist secreted frizzled-related protein-1 stimulates bone formation.
Hawkshaw NJ et al. (2018). PLOS Biology. University of ]
Ma Q et al. (2022). Journal of Bone and Mineral Research. The SFRP1 Inhibitor WAY-316606 Attenuates Osteoclastogenesis Through Dual Modulation of Canonical Wnt Signaling.
==========================================================
TABLE OF CONTENTS
==========================================================
WAY-316606 is a potent small-molecule inhibitor of Secreted Frizzled-Related Protein 1 (sFRP-1), developed originally by Wyeth Pharmaceuticals as a candidate drug for osteoporosis.
sFRP-1 is an endogenous antagonist of the Wnt signalling pathway. It sits in the extracellular space and physically intercepts Wnt ligand proteins before they can bind their receptors, acting as a molecular brake on one of the body's most important growth and regeneration pathways.
WAY-316606 binds directly to sFRP-1 (Kd = 0.08 uM) and neutralises it, releasing the brake and allowing Wnt/beta-catenin signalling to proceed. This single mechanism has downstream effects in multiple tissues:
Bone Hair follicles Neural tissue Periodontal ligament
Because sFRP-1 is expressed broadly across the body.
sFRP-1 is an endogenous antagonist of the Wnt signalling pathway. It sits in the extracellular space and physically intercepts Wnt ligand proteins before they can bind their receptors, acting as a molecular brake on one of the body's most important growth and regeneration pathways.
WAY-316606 binds directly to sFRP-1 (Kd = 0.08 uM) and neutralises it, releasing the brake and allowing Wnt/beta-catenin signalling to proceed. This single mechanism has downstream effects in multiple tissues:
Bone Hair follicles Neural tissue Periodontal ligament
Because sFRP-1 is expressed broadly across the body.
sFRP-1 is a naturally occurring protein that your body produces to suppress Wnt/beta-catenin signalling. Under normal conditions this brake is useful. The problem is that sFRP-1 expression increases significantly with age and in certain disease states.
IN BONE:
sFRP-1 levels are measurably elevated in osteoporotic patients vs healthy controls. The elevated sFRP-1 suppresses osteoblast (bone-building cell) activity while simultaneously supporting osteoclast (bone-destroying cell) survival. A double hit that tips the balance toward bone loss.
IN HAIR FOLLICLES:
sFRP-1 is expressed in the dermal papilla, the cellular engine at the base of each hair follicle. It suppresses Wnt/beta-catenin activity there, pushing follicles into catagen (regression phase) and slowing hair shaft production. In androgenetic alopecia, this suppression compounds the DHT-driven miniaturisation of follicles.
GENETIC CONFIRMATION:
Mice with the SFRP1 gene fully knocked out show significantly elevated bone mass, resistance to age-related bone loss, and improved fracture repair. Nature's own proof that sFRP-1 is a meaningful brake on regeneration.
IN BONE:
sFRP-1 levels are measurably elevated in osteoporotic patients vs healthy controls. The elevated sFRP-1 suppresses osteoblast (bone-building cell) activity while simultaneously supporting osteoclast (bone-destroying cell) survival. A double hit that tips the balance toward bone loss.
IN HAIR FOLLICLES:
sFRP-1 is expressed in the dermal papilla, the cellular engine at the base of each hair follicle. It suppresses Wnt/beta-catenin activity there, pushing follicles into catagen (regression phase) and slowing hair shaft production. In androgenetic alopecia, this suppression compounds the DHT-driven miniaturisation of follicles.
GENETIC CONFIRMATION:
Mice with the SFRP1 gene fully knocked out show significantly elevated bone mass, resistance to age-related bone loss, and improved fracture repair. Nature's own proof that sFRP-1 is a meaningful brake on regeneration.
The Wnt/beta-catenin pathway (canonical Wnt signalling) is one of the most conserved and fundamental signalling systems in biology. It governs:
Embryonic development and tissue patterning
Stem cell maintenance and activation
Cell proliferation, survival, and differentiation
Tissue regeneration and repair
HOW IT WORKS:
1. Wnt ligands are secreted and bind to Frizzled receptors + LRP5/6 co-receptors on target cells
2. This initiates a cascade that stabilises beta-catenin inside the cell
3. Stabilised beta-catenin translocates to the nucleus and activates target gene transcription
4. Those genes drive the tissue-specific response: bone formation in osteoblasts, hair shaft production in dermal papilla cells, neural differentiation in stem cells
sFRP-1 intercepts step 1 by physically grabbing Wnt ligands in the extracellular space. No binding = pathway stays silent.
WAY-316606 intercepts sFRP-1 by binding to sFRP-1's netrin-related motif (NTR) domain. Pathway gets to run again.
WHY WNT AND NOT SOMETHING ELSE:
Minoxidil and finasteride work downstream of the actual follicle biology. WAY-316606 targets the Wnt pathway, which IS the follicle's intrinsic growth machinery. Reactivating it is a fundamentally more direct intervention.
NOTE: Wnt is also an oncogenic pathway in many cancers. This is the primary safety concern. See section 07.
Embryonic development and tissue patterning
Stem cell maintenance and activation
Cell proliferation, survival, and differentiation
Tissue regeneration and repair
HOW IT WORKS:
1. Wnt ligands are secreted and bind to Frizzled receptors + LRP5/6 co-receptors on target cells
2. This initiates a cascade that stabilises beta-catenin inside the cell
3. Stabilised beta-catenin translocates to the nucleus and activates target gene transcription
4. Those genes drive the tissue-specific response: bone formation in osteoblasts, hair shaft production in dermal papilla cells, neural differentiation in stem cells
sFRP-1 intercepts step 1 by physically grabbing Wnt ligands in the extracellular space. No binding = pathway stays silent.
WAY-316606 intercepts sFRP-1 by binding to sFRP-1's netrin-related motif (NTR) domain. Pathway gets to run again.
WHY WNT AND NOT SOMETHING ELSE:
Minoxidil and finasteride work downstream of the actual follicle biology. WAY-316606 targets the Wnt pathway, which IS the follicle's intrinsic growth machinery. Reactivating it is a fundamentally more direct intervention.
NOTE: Wnt is also an oncogenic pathway in many cancers. This is the primary safety concern. See section 07.
Bodine PV et al. (2009). A small molecule inhibitor of the Wnt antagonist Secreted Frizzled-Related Protein-1 stimulates bone formation. Journal of Bone and Mineral Research.
Wyeth researchers screened a large chemical library for molecules that could block sFRP-1 and restore Wnt signalling in bone. WAY-316606 was the lead compound.
KEY FINDINGS:
Bound to sFRP-1 with Kd = 0.08 uM (extremely high affinity)
Inhibited sFRP-1 function with EC50 = 0.65 uM
Produced a ninefold increase in Wnt/beta-catenin signalling in reporter assay
Increased total bone area at concentrations as low as 0.0001 uM in murine calvarial assay
Also binds sFRP-2 (Kd = 1 uM), some cross-reactivity with the broader sFRP family
This paper established proof-of-concept: you can pharmacologically inhibit sFRP-1, the Wnt pathway responds, and bone formation increases.
Wyeth researchers screened a large chemical library for molecules that could block sFRP-1 and restore Wnt signalling in bone. WAY-316606 was the lead compound.
KEY FINDINGS:
Bound to sFRP-1 with Kd = 0.08 uM (extremely high affinity)
Inhibited sFRP-1 function with EC50 = 0.65 uM
Produced a ninefold increase in Wnt/beta-catenin signalling in reporter assay
Increased total bone area at concentrations as low as 0.0001 uM in murine calvarial assay
Also binds sFRP-2 (Kd = 1 uM), some cross-reactivity with the broader sFRP family
This paper established proof-of-concept: you can pharmacologically inhibit sFRP-1, the Wnt pathway responds, and bone formation increases.
Ma Q et al. (2022). The SFRP1 Inhibitor WAY-316606 Attenuates Osteoclastogenesis Through Dual Modulation of Canonical Wnt Signaling. Journal of Bone and Mineral Research.
Most osteoporosis drugs do one thing. WAY-316606 attacks osteoporosis from both sides simultaneously.
MECHANISM 1 PROMOTES OSTEOGENESIS (builds bone):
sFRP-1 inhibition frees Wnt/beta-catenin to activate osteoblast precursor cells, upregulating transcription factors RUNX2 and osterix that drive osteoblast maturation and mineralisation. More active osteoblasts = more bone matrix laid down.
MECHANISM 2 SUPPRESSES OSTEOCLASTOGENESIS (stops destruction):
Osteoclasts themselves express and secrete sFRP-1, which then acts autocrinally to support their own differentiation and survival. WAY-316606 disrupts both extracellular and intracellular sFRP-1 function. Result: osteoclast-specific gene expression is suppressed, bone resorption decreases.
IN VIVO VALIDATION:
In the ovariectomized (OVX) mouse model of postmenopausal osteoporosis, WAY treatment significantly improved bone density and trabecular architecture vs untreated controls.
VERDICT: Dual anabolic and anti-resorptive action from a single mechanism. This profile does not exist in any currently approved osteoporosis drug.
Most osteoporosis drugs do one thing. WAY-316606 attacks osteoporosis from both sides simultaneously.
MECHANISM 1 PROMOTES OSTEOGENESIS (builds bone):
sFRP-1 inhibition frees Wnt/beta-catenin to activate osteoblast precursor cells, upregulating transcription factors RUNX2 and osterix that drive osteoblast maturation and mineralisation. More active osteoblasts = more bone matrix laid down.
MECHANISM 2 SUPPRESSES OSTEOCLASTOGENESIS (stops destruction):
Osteoclasts themselves express and secrete sFRP-1, which then acts autocrinally to support their own differentiation and survival. WAY-316606 disrupts both extracellular and intracellular sFRP-1 function. Result: osteoclast-specific gene expression is suppressed, bone resorption decreases.
IN VIVO VALIDATION:
In the ovariectomized (OVX) mouse model of postmenopausal osteoporosis, WAY treatment significantly improved bone density and trabecular architecture vs untreated controls.
VERDICT: Dual anabolic and anti-resorptive action from a single mechanism. This profile does not exist in any currently approved osteoporosis drug.
REASON 1 SYSTEMIC WNT ACTIVATION RISK:
Wnt/beta-catenin is a well-established oncogenic pathway. A systemic drug that broadly upregulates Wnt raises real carcinogenesis concerns. Regulators will demand extensive long-term safety data before approving anything that touches this pathway systemically.
REASON 2 EXISTING COMPETITION:
Bisphosphonates and denosumab are cheap, well-characterised, and effective enough for most patients. The bar to displace them is extremely high.
REASON 3 OFF-TARGET TISSUE PROBLEM:
sFRP-1 is expressed in gut epithelium, liver, stem cell niches, brain. Systemically suppressing it means Wnt goes up everywhere, not just in bone. Pharmacologically targeting skeletal tissue specifically has not been solved.
REASON 4 THE PIPELINE PIVOT:
Interest has shifted toward topical delivery for hair, where local application limits systemic exposure, bypasses the cancer-risk regulatory hurdle, and targets a large cosmetic market with lower regulatory burden than a systemic disease drug.
Wnt/beta-catenin is a well-established oncogenic pathway. A systemic drug that broadly upregulates Wnt raises real carcinogenesis concerns. Regulators will demand extensive long-term safety data before approving anything that touches this pathway systemically.
REASON 2 EXISTING COMPETITION:
Bisphosphonates and denosumab are cheap, well-characterised, and effective enough for most patients. The bar to displace them is extremely high.
REASON 3 OFF-TARGET TISSUE PROBLEM:
sFRP-1 is expressed in gut epithelium, liver, stem cell niches, brain. Systemically suppressing it means Wnt goes up everywhere, not just in bone. Pharmacologically targeting skeletal tissue specifically has not been solved.
REASON 4 THE PIPELINE PIVOT:
Interest has shifted toward topical delivery for hair, where local application limits systemic exposure, bypasses the cancer-risk regulatory hurdle, and targets a large cosmetic market with lower regulatory burden than a systemic disease drug.
Hawkshaw NJ et al. (2018). PLOS Biology. University of Manchester.
The discovery did not start as a hair drug search. It started with a known anomaly:
Cyclosporine A (CsA), the immunosuppressant used in transplant patients, has a well-documented side effect of causing excessive hair growth (hypertrichosis). Nobody knew the mechanism.
Dr Nathan Hawkshaw used microarray gene expression analysis to compare dermal papilla cells treated with CsA against untreated controls. The single most significantly downregulated gene in CsA-treated cells was SFRP1.
CsA was suppressing sFRP-1. With sFRP-1 suppressed, Wnt/beta-catenin in the follicle was freed. The follicle stayed in anagen longer and produced more hair. That was the hypertrichosis mechanism.
This immediately suggested a drug target: specifically suppress sFRP-1 in the scalp without CsA's immunosuppressive toxicity. WAY-316606 was the obvious candidate from Bodine's prior bone work.
The discovery did not start as a hair drug search. It started with a known anomaly:
Cyclosporine A (CsA), the immunosuppressant used in transplant patients, has a well-documented side effect of causing excessive hair growth (hypertrichosis). Nobody knew the mechanism.
Dr Nathan Hawkshaw used microarray gene expression analysis to compare dermal papilla cells treated with CsA against untreated controls. The single most significantly downregulated gene in CsA-treated cells was SFRP1.
CsA was suppressing sFRP-1. With sFRP-1 suppressed, Wnt/beta-catenin in the follicle was freed. The follicle stayed in anagen longer and produced more hair. That was the hypertrichosis mechanism.
This immediately suggested a drug target: specifically suppress sFRP-1 in the scalp without CsA's immunosuppressive toxicity. WAY-316606 was the obvious candidate from Bodine's prior bone work.
Isolated human scalp follicles from donor tissue (including males with androgenetic alopecia) were treated with WAY-316606 ex vivo for 6 days.
RESULTS:
Significant increase in hair shaft elongation vs control
(n=31 control, 30 WAY-treated, from 3 male patient samples)
Increased K85 hair shaft keratin protein expression at 48 hours
(harder, thicker, more structurally mature hair fiber)
Inhibition of spontaneous catagen (follicle regression)
Measurable effects within 2 days of treatment
Ki-67/TUNEL analysis and Masson-Fontana staining confirmed findings histologically
CAVEAT: All data is ex vivo. Isolated follicles in a lab dish, not follicles on a living human scalp. The jump to in vivo involves blood supply, immune environment, DHT exposure, and other factors. No published human RCT results exist yet.
RESULTS:
Significant increase in hair shaft elongation vs control
(n=31 control, 30 WAY-treated, from 3 male patient samples)
Increased K85 hair shaft keratin protein expression at 48 hours
(harder, thicker, more structurally mature hair fiber)
Inhibition of spontaneous catagen (follicle regression)
Measurable effects within 2 days of treatment
Ki-67/TUNEL analysis and Masson-Fontana staining confirmed findings histologically
CAVEAT: All data is ex vivo. Isolated follicles in a lab dish, not follicles on a living human scalp. The jump to in vivo involves blood supply, immune environment, DHT exposure, and other factors. No published human RCT results exist yet.
MINOXIDIL:
Originally a blood pressure drug. Hair growth was a side effect. Mechanism involves vasodilation, VEGF upregulation, potassium channel effects. Does not address follicle miniaturisation at the biological level. Requires lifelong use, follicles revert when stopped.
FINASTERIDE:
Blocks 5-alpha reductase, preventing testosterone conversion to DHT. Works well hormonally but does not touch the follicle's intrinsic growth machinery. Risk of sexual side effects and post-finasteride syndrome.
WAY-316606 / sFRP-1 INHIBITION:
Targets the Wnt/beta-catenin pathway, the actual developmental machinery that determines whether a follicle grows, rests, or regresses. Does not care about DHT or blood pressure. Speaks directly to the follicle biology.
THEORETICAL ADVANTAGE:
Follicles already miniaturised and no longer responding to DHT-blocking may still retain functional Wnt pathway machinery. sFRP-1 inhibition could work on follicles past the point where finasteride helps. Unconfirmed but mechanistically plausible.
Originally a blood pressure drug. Hair growth was a side effect. Mechanism involves vasodilation, VEGF upregulation, potassium channel effects. Does not address follicle miniaturisation at the biological level. Requires lifelong use, follicles revert when stopped.
FINASTERIDE:
Blocks 5-alpha reductase, preventing testosterone conversion to DHT. Works well hormonally but does not touch the follicle's intrinsic growth machinery. Risk of sexual side effects and post-finasteride syndrome.
WAY-316606 / sFRP-1 INHIBITION:
Targets the Wnt/beta-catenin pathway, the actual developmental machinery that determines whether a follicle grows, rests, or regresses. Does not care about DHT or blood pressure. Speaks directly to the follicle biology.
THEORETICAL ADVANTAGE:
Follicles already miniaturised and no longer responding to DHT-blocking may still retain functional Wnt pathway machinery. sFRP-1 inhibition could work on follicles past the point where finasteride helps. Unconfirmed but mechanistically plausible.
MINOXIDIL 5% TOPICAL
Mechanism: vasodilation + VEGF + potassium channels (partially unclear)
Evidence: decades of human RCT data
Result: modest regrowth in 40-60% of users, lifelong use required
Addresses follicle miniaturisation directly: NO
Verdict: S-TIER accessibility, B-TIER mechanism depth
FINASTERIDE 1mg ORAL
Mechanism: DHT suppression via 5-alpha reductase inhibition
Evidence: multiple large RCTs
Result: halts progression in ~85%, regrowth in ~65% of men
Addresses follicle miniaturisation directly: PARTIALLY
Risk: sexual side effects, post-finasteride syndrome controversy
Verdict: S-TIER efficacy, risk profile requires individual assessment
DUTASTERIDE 0.5mg ORAL
Blocks both type I and II 5AR isoenzymes. Stronger DHT suppression (~90%+).
Higher efficacy, higher side effect risk. Prescription only.
Verdict: S+ TIER efficacy for the right candidate
WAY-316606 / sFRP-1 ANTAGONISTS
Mechanism: upstream Wnt/beta-catenin reactivation at the dermal papilla
Evidence: ex vivo human follicle data only. No human RCT published.
Theoretical advantage: works independent of DHT axis, potentially effective on miniaturised follicles that no longer respond to 5AR inhibitors
Accessibility: NOT AVAILABLE. Research chemical only.
Verdict: POTENTIAL S+ TIER. Unrated pending human data. Most mechanistically advanced compound in the pipeline.
Mechanism: vasodilation + VEGF + potassium channels (partially unclear)
Evidence: decades of human RCT data
Result: modest regrowth in 40-60% of users, lifelong use required
Addresses follicle miniaturisation directly: NO
Verdict: S-TIER accessibility, B-TIER mechanism depth
FINASTERIDE 1mg ORAL
Mechanism: DHT suppression via 5-alpha reductase inhibition
Evidence: multiple large RCTs
Result: halts progression in ~85%, regrowth in ~65% of men
Addresses follicle miniaturisation directly: PARTIALLY
Risk: sexual side effects, post-finasteride syndrome controversy
Verdict: S-TIER efficacy, risk profile requires individual assessment
DUTASTERIDE 0.5mg ORAL
Blocks both type I and II 5AR isoenzymes. Stronger DHT suppression (~90%+).
Higher efficacy, higher side effect risk. Prescription only.
Verdict: S+ TIER efficacy for the right candidate
WAY-316606 / sFRP-1 ANTAGONISTS
Mechanism: upstream Wnt/beta-catenin reactivation at the dermal papilla
Evidence: ex vivo human follicle data only. No human RCT published.
Theoretical advantage: works independent of DHT axis, potentially effective on miniaturised follicles that no longer respond to 5AR inhibitors
Accessibility: NOT AVAILABLE. Research chemical only.
Verdict: POTENTIAL S+ TIER. Unrated pending human data. Most mechanistically advanced compound in the pipeline.
This has to be addressed directly because it is the single biggest obstacle to WAY-316606 reaching humans.
Wnt/beta-catenin is constitutively activated (stuck ON) in:
80-90% of colorectal cancers
Hepatocellular carcinoma
Medulloblastoma
Triple-negative breast cancer
Gastric cancer
WHAT WE KNOW:
1. Topical delivery dramatically limits systemic exposure.
A scalp-applied formulation that stays in the skin keeps Wnt activation local to the follicle. This is a major difference from a systemic oral drug.
2. sFRP-1 has tumour suppressor properties in some cancers.
In breast and lung cancer, sFRP-1 expression is frequently reduced. The biology is tissue-specific. In bone and hair follicle, sFRP-1 is a pathological suppressor you want off. In some other tissues, you want it on.
3. Short-term local use is very different from chronic systemic exposure.
A topical scalp product is a fundamentally different risk profile from a daily oral drug taken for years.
4. SFRP1 knockout mice did not show dramatically elevated cancer rates.
Mildly reassuring but not conclusive for humans.
BOTTOM LINE:
The cancer risk for a well-formulated topical product is theoretical and likely manageable. For a systemic oral drug it is a real regulatory obstacle. This is why the topical hair route is advancing faster than the systemic bone route.
Wnt/beta-catenin is constitutively activated (stuck ON) in:
80-90% of colorectal cancers
Hepatocellular carcinoma
Medulloblastoma
Triple-negative breast cancer
Gastric cancer
WHAT WE KNOW:
1. Topical delivery dramatically limits systemic exposure.
A scalp-applied formulation that stays in the skin keeps Wnt activation local to the follicle. This is a major difference from a systemic oral drug.
2. sFRP-1 has tumour suppressor properties in some cancers.
In breast and lung cancer, sFRP-1 expression is frequently reduced. The biology is tissue-specific. In bone and hair follicle, sFRP-1 is a pathological suppressor you want off. In some other tissues, you want it on.
3. Short-term local use is very different from chronic systemic exposure.
A topical scalp product is a fundamentally different risk profile from a daily oral drug taken for years.
4. SFRP1 knockout mice did not show dramatically elevated cancer rates.
Mildly reassuring but not conclusive for humans.
BOTTOM LINE:
The cancer risk for a well-formulated topical product is theoretical and likely manageable. For a systemic oral drug it is a real regulatory obstacle. This is why the topical hair route is advancing faster than the systemic bone route.
Because sFRP-1 is expressed broadly, WAY-316606 has been studied in multiple other tissue contexts.
SUMMARY:
WAY-316606 is not just a hair or bone compound. It is a broad Wnt-pathway disinhibitor with measurable effects in every tissue that expresses sFRP-1. The challenge for any application is achieving tissue-specific delivery to avoid off-target effects elsewhere.
WAY-316606 loaded into composite hydrogels has been implanted into spinal cord injury (SCI) rat models. Results showed effective recruitment of endogenous neural stem cells to the lesion area, improved neuronal differentiation, and better functional outcomes vs untreated controls. Wnt/beta-catenin drives neural progenitor proliferation and differentiation, so the mechanism maps cleanly.
WAY-316606 increases mineralisation of periodontal ligament (PDL) cells and upregulates mineralisation-related genes including beta-catenin, alkaline phosphatase, osteocalcin, collagen I, and RUNX2. Potential application in periodontal disease bone regeneration, implant osseointegration, and alveolar bone loss. Same bone anabolic mechanism in a dental-specific context.
At higher doses (4 nM), WAY-316606 showed decreased IRF4 expression, a marker of M2 macrophage differentiation, in an allergic asthma mouse model. Very early stage, possibly off-target, not a current focus of development.
SUMMARY:
WAY-316606 is not just a hair or bone compound. It is a broad Wnt-pathway disinhibitor with measurable effects in every tissue that expresses sFRP-1. The challenge for any application is achieving tissue-specific delivery to avoid off-target effects elsewhere.
WAY-316606 itself has not completed published human clinical trials for any indication.
OSTEOPOROSIS:
Wyeth's original program did not advance to Phase 2/3 trials. No current sponsor appears to be actively developing WAY-316606 specifically for bone.
HAIR LOSS:
Following the 2018 Manchester paper, Italian pharmaceutical company Giuliani Pharma announced plans for clinical trials in September 2018. Giuliani's actual program: developing analogs of WAY-316606 optimised for cosmetic topical use, not WAY-316606 itself. Prof. Ralf Paus confirmed the analog development direction. No completed human RCT results published as of current date.
All published efficacy data remains ex vivo.
OSTEOPOROSIS:
Wyeth's original program did not advance to Phase 2/3 trials. No current sponsor appears to be actively developing WAY-316606 specifically for bone.
HAIR LOSS:
Following the 2018 Manchester paper, Italian pharmaceutical company Giuliani Pharma announced plans for clinical trials in September 2018. Giuliani's actual program: developing analogs of WAY-316606 optimised for cosmetic topical use, not WAY-316606 itself. Prof. Ralf Paus confirmed the analog development direction. No completed human RCT results published as of current date.
All published efficacy data remains ex vivo.
The compound to track is NOT WAY-316606 itself.
It is the Giuliani Pharma sFRP-1 antagonist analog designed for topical cosmetic delivery.
KEY MILESTONES TO WATCH:
Phase 1 safety data in humans for topical sFRP-1 antagonist
Phase 2 RCT with hair count endpoints (terminal hair count per cm2)
Combination trial data: sFRP-1 inhibitor + minoxidil or + finasteride
SEARCH TERMS TO TRACK PROGRESS:
"sFRP1 antagonist alopecia clinical trial"
"Giuliani Pharma hair"
"WAY-316606 analog topical"
It is the Giuliani Pharma sFRP-1 antagonist analog designed for topical cosmetic delivery.
KEY MILESTONES TO WATCH:
Phase 1 safety data in humans for topical sFRP-1 antagonist
Phase 2 RCT with hair count endpoints (terminal hair count per cm2)
Combination trial data: sFRP-1 inhibitor + minoxidil or + finasteride
SEARCH TERMS TO TRACK PROGRESS:
"sFRP1 antagonist alopecia clinical trial"
"Giuliani Pharma hair"
"WAY-316606 analog topical"
WAY-316606 is a molecule that blocks a protein called sFRP-1. sFRP-1's job is to suppress the Wnt pathway, one of the most important biological switches for tissue growth and regeneration.
When you block sFRP-1 with WAY-316606, the Wnt pathway can run again.
IN BONE:
Osteoblasts start building new bone AND osteoclasts stop destroying it. Dual anti-osteoporosis effect from a single mechanism. No existing drug does both.
IN HAIR FOLLICLES:
Dermal papilla cells get the Wnt signal to stay in growth phase, produce more keratin, and resist regression. More hair growth, thicker hair fibers, delayed follicle regression.
IN NEURAL TISSUE:
Neural stem cells are recruited to injury sites and differentiate more effectively. Experimental regeneration research.
WHY IT IS NOT AVAILABLE YET:
Systemic Wnt activation raises legitimate cancer concerns. The bone application needs systemic delivery, which is the hard problem. The hair application gets around this with topical delivery, which is why hair is advancing faster.
WHAT TO EXPECT:
The Giuliani Pharma topical sFRP-1 antagonist analog entering human trials is the event to watch. When Phase 2 hair count data arrives, this will either become the most mechanistically significant new hair loss treatment in decades, or reveal that the ex vivo results do not translate to living scalp tissue.
OVERALL VERDICT: PRE-CLINICAL S-TIER
Most mechanistically advanced compound across both hair loss and bone anabolism pipelines. Nothing currently available touches the Wnt pathway this cleanly. The wait is real but so is the science.
When you block sFRP-1 with WAY-316606, the Wnt pathway can run again.
IN BONE:
Osteoblasts start building new bone AND osteoclasts stop destroying it. Dual anti-osteoporosis effect from a single mechanism. No existing drug does both.
IN HAIR FOLLICLES:
Dermal papilla cells get the Wnt signal to stay in growth phase, produce more keratin, and resist regression. More hair growth, thicker hair fibers, delayed follicle regression.
IN NEURAL TISSUE:
Neural stem cells are recruited to injury sites and differentiate more effectively. Experimental regeneration research.
WHY IT IS NOT AVAILABLE YET:
Systemic Wnt activation raises legitimate cancer concerns. The bone application needs systemic delivery, which is the hard problem. The hair application gets around this with topical delivery, which is why hair is advancing faster.
WHAT TO EXPECT:
The Giuliani Pharma topical sFRP-1 antagonist analog entering human trials is the event to watch. When Phase 2 hair count data arrives, this will either become the most mechanistically significant new hair loss treatment in decades, or reveal that the ex vivo results do not translate to living scalp tissue.
OVERALL VERDICT: PRE-CLINICAL S-TIER
Most mechanistically advanced compound across both hair loss and bone anabolism pipelines. Nothing currently available touches the Wnt pathway this cleanly. The wait is real but so is the science.
==========================================================
mass tag stolen from @Dragon
